Comparative Pharmacology
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus TELDRIN.
EPINASTINE HYDROCHLORIDE vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist. Inhibits histamine release from mast cells and basophils, and reduces chemotaxis and activation of eosinophils. Also suppresses cytokine production from T lymphocytes.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
For allergic rhinitis and urticaria: 10 mg twice daily orally (20 mg/day). For ophthalmic use: 1 drop in affected eye(s) twice daily of 0.05% solution.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 5.7 to 9.2 hours in healthy adults. In elderly patients, the half-life may be prolonged due to reduced renal function. The half-life supports twice-daily dosing for most indications.
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal excretion accounts for approximately 39% of the administered dose, with about 28% as unchanged drug and 11% as metabolites. Fecal excretion is minimal at approximately 10%. Biliary excretion is not a significant route. Overall, renal clearance is the primary elimination pathway.
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine